Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $338 - $362
1 Added 0.06%
1,667 $579,000
Q2 2023

Jul 26, 2023

SELL
$314.42 - $351.91 $4,401 - $4,926
-14 Reduced 0.83%
1,666 $586,000
Q1 2023

May 15, 2023

BUY
$283.23 - $323.1 $475,826 - $542,808
1,680 New
1,680 $529,000
Q4 2022

Jan 26, 2023

SELL
$285.76 - $321.48 $6,572 - $7,394
-23 Reduced 1.33%
1,704 $492,000
Q3 2022

Nov 08, 2022

SELL
$273.83 - $305.53 $10,405 - $11,610
-38 Reduced 2.15%
1,727 $500,000
Q2 2022

Aug 05, 2022

BUY
$234.96 - $292.55 $414,704 - $516,350
1,765 New
1,765 $497,000
Q4 2020

Jan 29, 2021

SELL
$207.01 - $276.09 $75,558 - $100,772
-365 Closed
0 $0
Q3 2020

Oct 29, 2020

SELL
$255.65 - $303.1 $660,599 - $783,210
-2,584 Reduced 87.62%
365 $99,000
Q2 2020

Aug 10, 2020

BUY
$225.48 - $295.8 $601,580 - $789,194
2,668 Added 949.47%
2,949 $856,000
Q2 2019

Jul 19, 2019

SELL
$164.61 - $190.37 $2,798 - $3,236
-17 Reduced 5.7%
281 $52,000
Q4 2018

Jan 29, 2019

BUY
$151.91 - $192.21 $15,494 - $19,605
102 Added 52.04%
298 $49,000
Q2 2018

Aug 14, 2018

SELL
$145.72 - $169.96 $715,922 - $835,013
-4,913 Reduced 96.16%
196 $33,000
Q1 2018

May 02, 2018

BUY
$151.6 - $177.13 $2,577 - $3,011
17 Added 0.33%
5,109 $833,000
Q4 2017

Feb 14, 2018

BUY
$137.28 - $155.55 $57,520 - $65,175
419 Added 8.97%
5,092 $763,000
Q3 2017

Nov 07, 2017

SELL
$148.13 - $162.24 $38,661 - $42,344
-261 Reduced 5.29%
4,673 $710,000
Q2 2017

Aug 11, 2017

BUY
N/A
4,934
4,934 $636,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Hanseatic Management Services Inc Portfolio

Follow Hanseatic Management Services Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hanseatic Management Services Inc, based on Form 13F filings with the SEC.

News

Stay updated on Hanseatic Management Services Inc with notifications on news.